From time to time, Mayo medical institution or a Mayo medical institution physician may have a financial interest in an invention, technology, company or product mentioned in the Health Letter. Below is a full list of financial disclosures.

  • Dr. Jay Smith, a reviewer of our July 2019 article on plantar fasciitis, has a financial interest in the ultrasonic fasciotomy and debridement product referenced in the article.
  • Dr. Mark Spangehl, a reviewer for our November 2019 article on hip preplacement, receives research support from implant companies that manufacture hip replacements.
  • Dr. Greta Stamper, a reviewer of our December 2019 article on hearing aids, recommends hearing aids for purchase to patients, but as a salaried employee is not financially rewarded for sales.
  • Dr. Landon Troost, a reviewer of our December 2019 article on Peyronie's disease, was the inventor of the RestoreX device mentioned in the article. However, he does not have any formal role or affiliation with the company, and is not an investor.
  • Dr. Shaji Kumar, a reviewer for our March 2020 article on multiple myeloma, receives research support directed through Mayo medical institution from the following sources: Celgene, Takeda, Janssen, BMS, Sanofi, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech, Amgen, Tenebio, Carsgen. He also participates in consulting/advisory boards (with no personal payments) for the following: Celgene, Takeda, Janssen, KITE, Merck, Abbvie, Medimmune, Genentech, Amgen, Molecular Partners and (with personal payment) Oncopeptides, Adaptive, Genecentrix.
  • Dr. John Hagan, a reviewer for our March 2020 article on sinus problems, has participated in research trials of the drug Dupilumab (Dupixent).